oligodendrocytes migrate from the corpus callosum into the overlying cortex. The incidence of cilia did not change markedly across age groups, and did not vary consistently with the number of processes per cell, which was used as an indication of the maturation stage of OPCs and young OLs. The mean percent of Olig1 immunopositive (Olig1+) cells having cilia across ages was 33.1% + 16.5%, with all ages combined. In O4+ cells of these mice, 56.7 + 3.6% had primary cilia. If it is the case that adult OLs do not have cilia, the point in the lineage when primary cilia are lost is still unknown. Adult mice that had been injected with cyclopamine to block cilia-dependent Shh signaling were examined to determine whether the rate of generating new OPCs was influenced. In the CC of control mice, the numerical density of Olig1+/BrdU+ cells was 1.29 + 0.07/mm2 was reduced to 0.68 + 0.38/mm2 in the cyclopamine-injected group, and the numerical density of all BrdU+ cells (including both Olig1+ and Olig1- cells) of 4.55 + 1.50/mm2 in the control group was reduced to 3.14 + 1.27/mm2 in the cyclopamine-injected group. However, there were only 2 mice in each group and the differences were not statistically significant.

Each year, aging and age-related deficits in cognitive function affect larger population worldwide. Research on aging has focused on changes in gray matter and white matter with age. A quantitative analysis of magnetic resonance images from healthy subjects of 16-79 years showed a significant negative correlation between gray matter volume and age (Taki et al., 2004). In addition, age-related cognitive decline is reported to be associated with white matter changes such as myelin damage, a result of both the inability of microglia to clear out damaged myelin debris and oligodendrocyte to support remyelination. Eotaxin-1 (CCL11) belongs to a group of eosinophil-specific chemoattractant originally found in peripheral immune system mediating allergic inflammation, asthma and atopic dermatitis (Garcia-Zepeda et al., 1996; Spergel, Mizoguchi, Oettgen, Bhan, & Geha, 1999). Recently it has been reported to have endogenous sources in the CNS and to increase with age in cerebral spinal fluid (CSF) as well as periphery in blood plasma. While CCL11 has been identified to increase with age, injection of CCL11 inhibit neurogenesis in young mice, which is likely to be mediated by C-C chemokine receptor type 3 (CCR3). CCR3 is also the only receptor for CCL11 that is expressed by oligodendrocyte precursor cells (OPCs) and by activated microglia in mice, which means it may participate in the process of microglial phagocytosis and oligodendrocyte myelination. To investigate if CCR3 is an important factor in the normal aging brain and its potential role in these existing findings, immunohistochemistry, stereology and densitometry were performed in the anterior cingulate cortex and cingulum from brain tissue of 4 young adults and 6 aged rhesus monkeys that were behaviorally tested previously to 1) demonstrate any association between CCR3 expression level and age 2) characterize changes in CCR3 level in relation to cognitive impairment 3) identify cellular localization of CCR3. We found a significant increase in amount of CCR3 cingulate cortex with age, which suggests its pro-disease effect in other pathways such as the interaction between CNS and T cell immune system. Although for aged group increase in CCR3+ cell density in white matter appeared insignificant, we found that CCR3 was expressed exclusively in OPCs but was absent in mature oligodendrocytes. indicating its role in OPC proliferation, oligodendrocyte maturation and myelination.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第22040号 / 医博第4525号 / 新制||医||1038(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 高橋 淳, 教授 伊佐 正, 教授 渡邉 大 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

In the brain, axons are wrapped by myelin sheaths which ensure fast saltatory conduction of impulses and provide metabolic support. In multiple sclerosis (MS), the myelin sheaths are lost which leaves the axon denuded. This not only results in slower conduction of action potentials, but if prolonged, can also lead to axon death due to the loss of metabolic support. This neurodegeneration is the main cause of permanent disability in multiple sclerosis patients. The axon death and disability which stem from it could be prevented by restoring the myelin wrap before axon damage has occurred. This remyelination process is carried out by oligodendrocyte precursor cells which are present throughout life. To remyelinate, OPCs migrate to the area of damage and differentiate into myelinating oligodendrocytes which ensheathe axons with new myelin. In multiple sclerosis, this process occurs but is insufficient to overcome the damage. Therefore, central to the therapeutic efforts in multiple sclerosis is the aim to improve endogenous remyelination. Enhancing recruitment of oligodendrocyte precursor cells (OPCs) to the areas of damage is a clinically unexplored target. To investigate the therapeutic potential of OPC recruitment modulators, I have looked at 2 different targets involved in migration NDST1/HS and Sema3A/NP1. The first target, heparan sulfate (HS) is a proteoglycan which is important to OPC migration, investigated by Pascale Durbec's group in France. In a demyelinating mouse model, its key synthesising enzyme, NDST1, is upregulated by oligodendroglia in a belt around the lesion to aid OPC recruitment. Loss of NDST1 in oligodendrocytes was found to impair remyelination and reduce OPC migration in mice. In collaboration with them, I investigated the relevance of this molecule in post-mortem MS human tissue. I found that in human as well as mouse, NDST1 was primarily expressed by oligodendroglia. The protein level and the proportion of oligodendroglia expressing NDST1 was increased in MS compared to control indicating NDST1 upregulation as a disease response in human. We also found that low numbers of NDST1+ oligodendroglia correlate with bigger sizes of lesions and chronic lesion types that fail to repair, highlighting its importance in repair. Moreover, high numbers of NDST1+ cells in a patient correlated with increased remyelination potential. This indicates that in human, intra-patient variation in NDST1 level may explain differences in potential for endogenous repair. Secondly, I looked at Sema3A, a chemorepulsive molecule which is upregulated in demyelinated injury rodent models aswell as multiple sclerosis lesions, particularly in OPC-depopulated chronic active lesions. Research has consistently found that the level of Sema3A negatively correlates to remyelination because Sema3A hinders OPC migration. This has highlighted Sema3A as a potential target to improve OPC recruitment in MS however the size and shape of the molecule make it hard to design therapeutics against it. Therefore, I looked at its druggable receptor, Neuropilin 1 (NP1), to see whether inhibition of NP1 had the same positive effect on OPC recruitment and remyelination as lowering the level of Sema3A. NP1 is a tyrosine kinase receptor for both Sema3A and vascular endothelial growth factor (VEGF) and is found in many cell types. To check if NP1 inhibition is beneficial, I assessed remyelination in a mouse where the Sema3A binding site of NP1 has been mutated to prevent Sema3A binding and exerting its effect. This is a proxy for a (currently unavailable) ideal NP1 inhibitor of the Sema3A site only. Contrary to my expectations, OPC recruitment and remyelination in the mutant mice were not improved. However, the NP1 mutation resulted in an altered immune response. To exclude the possibility that no improvement in the OPC recruitment and remyelination of those mice was seen because it was negated by the altered immune response, I explored a cell specific mutant mouse in which NP1 was deleted in oligodendroglia only. In this mutant as well, I did not see improvement of OPC recruitment and remyelination. I therefore propose that Neuropilin 1 is not imperative for Sema3As action in remyelination and is not suitable as a therapeutic target in multiple sclerosis. Loss of the whole NP1, but not loss of the Sema3A site also resulted in biggermyelinated and unmyelinated axons as well as a different myelin thickness post remyelination. This showed that VEGF and the VEGF site on NP1 in oligodendroglia have a previously unknown but important role in determining axon size and myelin thickness which should be further investigated. To further elucidate those results in a simple system, I looked at how Sema3A, NP1-Sema3A inhibitors, VEGF and NP1-VEGF inhibitor affect OPC behaviour. I confirmed Sema3As chemorepulsive effect but also showed that at different concentrations it can improve proliferation and survival of OPCs. Inhibiting the Sema3A site and the VEGF site of NP1 by specific blocking antibodies also affects OPC proliferation and maturation. This suggested that NP1s ligands are involved in more than just OPC migration. In summary, this work supports the relevance of the mouse findings that NDST1 is upregulated in demyelination and important for repair for human illustrating that it might be a suitable therapeutic target to investigate. However, despite the importance of Sema3A in MS models, its only reported receptor, NP1, is not essential for Sema3As action. Therefore, it is an unsuitable therapeutic target. The fact that NP1 is an inappropriate drug target for MS is further demonstrated by the involvement of its ligands in multiple OPC behaviours both in positive and negative aspects.

Neonatal hydrocephalus is a common neurological disorder leading to expansion of the cerebral ventricles. This disease is associated with significant morbidity and mortality and is often fatal if left untreated. Hydrocephalus was first described over 2500 years ago by Hippocrates, the father of medicine, and remains poorly understood today. Current therapies still rely on invasive procedures developed over 60 years ago that are associated with high failure and complication rates. Thus, the identification of molecular mechanisms and the development of non-invasive medical treatments for neonatal hydrocephalus are high priorities for the medical and scientific communities. The prevailing doctrine in the field is that hydrocephalus is strictly a "plumbing problem" caused by impaired cerebrospinal fluid (CSF) flow. Recently, animal models with impaired cilia have provided insight into the mechanisms involved in communicating (non-obstructive) hydrocephalus. However, as a result of a poor understanding of hydrocephalus, no animal studies to date have identified an effective non-invasive treatment. The goal of this thesis project is to investigate the molecular mechanisms underlying this disease and to identify a non-invasive, highly effective treatment strategy. In Chapter 2, we utilize a novel animal model with idiopathic hydrocephalus, mimicking the human ciliopathy Bardet-Biedl Syndrome (BBS), to examine the role of cilia in hydrocephalus. We find that these mice develop communicating hydrocephalus prior to the development of ependymal "motile" cilia, suggesting that this phenotype develops as a result of dysfunctional "primary" cilia. Primary cilia are non-motile and play a role in cellular signaling. These results challenge the current dogma that dysfunctional motile cilia underlies neonatal hydrocephalus and implicate a novel role for primary cilia and cellular signaling in this disease. Chapter 3 focuses on identifying the link between primary cilia and neonatal hydrocephalus. In this chapter, we report that disrupting the molecular machinery within primary cilia leads to faulty PDGFRα signaling and the loss of a particular class of neural progenitor cells called oligodendrocyte precursor cells (OPCs). We find that the loss of OPCs leads to neonatal hydrocephalus. Importantly, we identify the molecular mechanism underlying both the loss of OPCs and the pathogenesis of neonatal hydrocephalus. Chapter 4 explores the therapeutic potential of targeting the defective cellular signaling pathways to treat neonatal hydrocephalus. By targeting the faulty signaling, we restore normal development of oligodendrocyte precursor cells, and curtail the development of hydrocephalus. This work challenges the predominant view of hydrocephalus being strictly a "plumbing problem" treatable solely by surgical diversion of CSF. Here, we propose that hydrocephalus is a neurodevelopmental disorder that can be ameliorated by non-invasive means. Importantly, we introduce novel molecular targets and a non-invasive treatment strategy for this devastating disorder. To our knowledge, we are the first to successfully treat neonatal hydrocephalus in any model organism by targeting neural progenitor cells.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第22336号 / 医博第4577号 / 新制||医||1041(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 高橋 淳, 教授 渡邉 大, 教授 伊佐 正 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Yes / Expression of the transmembrane NG2 chondroitin sulphate proteoglycan (CSPG) defines a distinct population of NG2-glia. NG2-glia serve as a regenerative pool of oligodendrocyte progenitor cells in the adult central nervous system (CNS), which is important for demyelinating diseases such as multiple sclerosis, and are a major component of the glial scar that inhibits axon regeneration after CNS injury. In addition, NG2-glia form unique neuron–glial synapses with unresolved functions. However, to date it has proven difficult to study the importance of NG2-glia in any of these functions using conventional transgenic NG2 ‘knockout’ mice. To overcome this, we aimed to determine whether NG2-glia can be targeted using an immunotoxin approach. We demonstrate that incubation in primary anti-NG2 antibody in combination with secondary saporin-conjugated antibody selectively kills NG2-expressing cells in vitro. In addition, we provide evidence that the same protocol induces the loss of NG2-glia without affecting astrocyte or neuronal numbers in cerebellar brain slices from postnatal mice. This study shows that targeting the NG2 CSPG with immunotoxins is an effective and selective means for killing NG2-glia, which has important implications for studying the functions of these enigmatic cells both in the normal CNS, and in demyelination and degeneration.

京都大学 / 新制・課程博士 / 博士(医学) / 甲第24839号 / 医博第5007号 / 新制||医||1068(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 井上, 治久, 教授 寺田, 智祐, 教授 林, 康紀 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Les gliomes sont des tumeurs qui seforment par prolifération anormale de cellules dansle tissu cérébral. La dangerosité de ces tumeursréside dans le fait que la plupart des gliomes sontinvasifs : les cellules tumorales migrent dans le tissusain autour de la tumeur. Ces cellules tumoralesisolées provoquent des récidives quasi systématiquesaprès traitement (chirurgie, chimiothérapie,radiothérapie), rendant ces tumeurs incurablesactuellement et conduisant au décès du patient. Il estimportant d'associer des études fondamentales pourmieux comprendre leur évolution dès l'origine et desétudes plus appliquées en développant de nouveauxsubstrats pour reproduire in vitro leur évolution. Lescellules progénitrices des oligodendrocytes (OPC)représentent la plus grande population de cellules enprolifération et la plus largement distribuée dans lecerveau adulte, ce qui en fait un suspect idéal del’origine des gliomes. A partir de donnéesexpérimentales de la littérature sur la dynamique invivo de ces cellules, un modèle mathématiquereproduisant cette dynamique dans un tissu sain a étédéveloppé.Ce modèle montre également que les OPC pourraientêtre à l’origine de toutes les formes de gliomerencontrées aussi bien de bas grade que de hautgrade. Par ailleurs, l’approche expérimentale utiliséevisait à développer un substrat de culture cellulaireadapté à l’étude des gliomes in vitro. Ainsi, unhydrogel biocompatible, minimaliste et contrôlable aété élaboré. Celui-ci mime l’élasticité de la matriceextracellulaire (MEC) cérébrale avec une rigidité del’ordre de 200 Pa et l’effet adhésif des molécules dela MEC impliqué dans l’adhésion et la proliférationdes cellules tumorales. Grâce à ses propriétés,l’hydrogel favorise la survie de près de 90% desmodèles cellulaires de gliome utilisés dans notreétude et supporte la croissance en trois dimensionsd’agrégats multicellulaires semblables à lamorphologie de micro-tumeurs in vivo. Le modèled’hydrogel est donc validé pour favoriser la viabilitéet la prolifération cellulaires. Les perspectives detravail futures porteront sur l'optimisation de sacomposition pour mimer de manière encore plusréaliste la croissance tumorale in vivo. / Gliomas are brain tumors arising fromanomalous cell proliferation into the brain tissue.The hazard of these tumors resides in their invasiveability : tumor cells migrate into the healthy tissuesurrounding the tumor. These isolated cells causequasi systematic recurrences after treatment(surgery, chemotherapy, radiotherapy) making thesetumors currently incurable and leading to patientdeath. Hence, it is important to associatefundamental studies for better understanding of theirevolution from their origin with more appliedstudies developing new substrates for reproducingtheir evolution in vitro. Oligodendrocyte progenitorcells (OPC) are the most widely spread proliferatingpopulation in the adult brain, which makes them themain suspect of causing gliomas origin. Fromexperimental data in the literature about in vivodynamic of OPC, a mathematical model that depictsthis dynamic into a healthy tissue has beendeveloped.This model also shows that OPC could be at theorigin of all glioma forms from low to high grade.Furthermore, the experimental approach used aimedat designing a cell culture substrate adapted toglioma studies in vitro. Thus, a biocompatible,minimalistic and controllable hydrogel has beenperformed. It mimics brain extracellular matrix(ECM) elasticity around 200 Pa and the adhesiveeffect of ECM molecules involved in tumor celladhesion and proliferation. Due to these properties,the hydrogel contributes to around 90% of gliomacell models survival used in our study and promotesmulticellular aggregates growth in three dimensionsthat look like in vivo microtumors morphology. Thishydrogel model is thus validated for cell viabilityand proliferation. Future works will be devoted tothe optimization of its composition for bettermimicking of tumor growth in vivo in a morerealistic manner.

No description available.